Sequential Thrombolytic Therapy for Stroke Clot Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thrombolytic drugs for treating blood clots, such as tPA, are limited by their ability to cause bleeding due to degradation of hemostatic fibrin and the need for diagnostic confirmation before administration, which delays treatment and reduces efficacy, especially in stroke patients.
Innovation Solution
Administering a mini-dose of tPA followed by a mutant pro-urokinase (mproUK) with a waiting period to allow tPA clearance, significantly reducing the required dosage of mproUK and minimizing hemorrhagic side effects while achieving higher arterial patency rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current thrombolytic drugs (tPA) are administered to dissolve blood clots, then clot lysis is achieved, but bleeding risk increases due to degradation of hemostatic fibrin and clotting factors
Solution Approach 1:
The treatment is divided into multiple sequential phases: initial tPA administration, waiting period for tPA clearance, followed by proUK/mproUK administration. This segmentation allows each drug to act independently at optimized doses, achieving synergistic clot lysis while minimizing individual drug toxicity and fibrinogen degradation
Solution Approach 2:
The protocol employs periodic administration with a specific waiting period (at least two half-lives of tPA, approximately 10 minutes) between tPA and proUK/mproUK doses. This periodic action allows tPA to be cleared from circulation before administering the second agent, preventing overlapping effects that would increase bleeding risk while maintaining therapeutic efficacy
2Reliability
If diagnostic confirmation (CT scan or MRI) is performed before thrombolytic administration to ensure stroke is not caused by bleeding, then patient safety is improved, but treatment time is delayed reducing efficacy
Solution Approach 1:
A mini-dose of tPA (2-5 mg, significantly lower than standard 100 mg) is administered as a preliminary action before diagnostic confirmation. This mini-dose is sufficient to initiate clot lysis but too small to cause severe bleeding complications, allowing treatment to begin immediately while maintaining an acceptable safety profile even without immediate imaging confirmation
Solution Approach 2:
The dosage parameter of tPA is dramatically reduced from the standard 100 mg to a mini-dose of 2-5 mg. This parameter change transforms the risk-benefit profile, making the drug safe enough for empiric use without immediate imaging while still providing therapeutic benefit. The low dose minimizes fibrinogen degradation and bleeding risk even if the stroke turns out to be hemorrhagic
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in almost twice the clot lysis rate with a two-fold lower percentage of fibrinogen degradation, achieving maximum arterial patency with minimal bleeding risks, allowing for safer and more effective treatment of stroke and heart attack patients without the need for immediate diagnostic testing.
Implementation Method 1
thrombolytic drugs such as tissue plasminogen activator (tPA) and its derivatives in current use function by activating the proenzyme plasminogen to the protease plasmin
Implementation Method 2
plasmin, which degrades the fibrin mesh in the blood clot and makes the clot soluble
Implementation Method 3
mutant pro-urokinase plasminogen activator (mproUK)
Data Source
AI summary
Provided herein are methods for use in safe and effective thrombolysis, e.g., in therapy for a potential stroke or acute myocardial infarction (“AMI”) at a maximum arterial patency rate with minimal associated hemorrhagic side effects.